Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 6:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Identical Placebo tablet Clear all
Completed Not applicable Interventional

Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder

NCT00158028
View directory record Official record
Conditions
Schizotypal Personality Disorder
Interventions
Risperidone, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy

NCT03064568
View directory record Official record
Conditions
Myomectomy; Surgical Blood Loss
Interventions
Misoprostol 200Mcg Tab, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
3
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 27, 2026, 6:14 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

NCT07143968
View directory record Official record
Conditions
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, HIV (Human Immunodeficiency Virus)
Interventions
Resmetirom, Placebo Control
Drug
Lead sponsor
Naga P. Chalasani
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 27, 2026, 6:14 AM EDT
Recruiting Phase 2 Interventional

Limiting AAA With Metformin (LIMIT) Trial

NCT04500756
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
Metformin, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 95 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 2 Interventional

A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome

NCT02126995
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
MG01CI extended-release tablet
Drug
Lead sponsor
Alcobra Ltd.
Industry
Eligibility
15 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 27, 2026, 6:14 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

NCT01156051
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder, Insomnia, Sleep Disorders
Interventions
Guanfacine extended-release tablets, Placebo comparator
Drug
Lead sponsor
Children's Specialized Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Hamilton, New Jersey • Toms River, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

NCT01164501
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
BI 10773, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Anaheim, California • Lomita, California • Plantation, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 4 Interventional Results available

Acetaminophen (Tylenol) for Mood and Memory Changes Associated With Corticosteroid Therapy

NCT00377364
View directory record Official record
Conditions
Asthma, Rheumatic Disease
Interventions
Drug: Acetaminophen, Drug: Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis

NCT01066364
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Colesevelam Hcl
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 2 Interventional

A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus

NCT02673476
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALS-008176, Placebo
Drug
Lead sponsor
Alios Biopharma Inc.
Industry
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
11
States / cities
Eustis, Florida • Hialeah, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Metformin Effect on Brain Function in Insulin Resistant Elderly People

NCT03733132
View directory record Official record
Conditions
Insulin Resistance, Obesity, Obesity, Abdominal
Interventions
Metformin Hydrochloride, Placebo Oral Tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 2 Interventional

A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients

NCT01086748
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Placebo, LY2140023
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Escondido, California • Garden Grove, California • Paramount, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Not applicable Interventional Results available

Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis

NCT01755455
View directory record Official record
Conditions
Cystic Fibrosis, Anemia, Iron-Deficiency
Interventions
Ferrous sulfate 325mg, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Portland, Maine • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

CTS-1027 in Interferon-Naive Hepatitis C Patients

NCT00925990
View directory record Official record
Conditions
Hepatitis C
Interventions
ribavirin, CTS-1027, Placebo for ribavirin
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Not applicable Interventional

Randomized, Double-Blind Placebo-Controlled Trial to Assess Overall User Experience of a Synbiotic Vaginal Suppository

NCT06236893
View directory record Official record
Conditions
Vaginal Personal Care
Interventions
VH-01 vaginal suppository tablet, Placebo vaginal suppository tablet
Other
Lead sponsor
Seed Health
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Acute Effects of a Dietary Supplement on Cognitive Performance in Highly Trained Athletes.

NCT05926050
View directory record Official record
Conditions
Reaction Time
Interventions
Treatment (CopaPrime+ (USANA Health Sciences), Placebo
Dietary Supplement · Other
Lead sponsor
USANA Health Sciences
Industry
Eligibility
18 Years to 30 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Park City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder

NCT03017508
View directory record Official record
Conditions
Social Anxiety Disorder, Performance Anxiety
Interventions
BHV-0223, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Sep 27, 2026, 6:14 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Zelquistinel
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 64 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Montclair, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 27, 2026, 6:14 AM EDT
Recruiting Phase 2 Interventional

Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD

NCT03667846
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Alcohol Use Disorder
Interventions
Topiramate, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 27, 2026, 6:14 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Gut Microbiome Response to Long-Haul Travel in Elite Football Players

NCT07585474
View directory record Official record
Conditions
Microbial Composition, Immune Function
Interventions
Probiotic Capsule, Placebo
Drug
Lead sponsor
Sheffield Hallam University
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does Treatment With Macrobid Reduce Urinary Tract Infections in Patients Receiving a Sub-Urethral Sling for Incontinence

NCT00734968
View directory record Official record
Conditions
Stress Incontinence
Interventions
Nitrofurantoin, Placebo
Drug · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older · Female only
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00706654
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
937 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
39
States / cities
Cerritos, California • Escondido, California • Garden Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 4 Interventional Results available

A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia

NCT05597020
View directory record Official record
Conditions
Insomnia Disorder, Nocturia
Interventions
Daridorexant, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
55 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Miami Beach, Florida • Pompano Beach, Florida • Weston, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures

NCT00772603
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Placebo, 2400mg SPN-804, 1200mg SPN-804
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
23
States / cities
Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 27, 2026, 6:14 AM EDT